Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib With or Without Camrelizumab in HRD+ HER2- Advanced Breast Cancer
NCT05656131Phase 2Suspended
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib, camrelizumab in breast cancer. Started Nov 2022; status: suspended.
02
Drugs
fluzoparibcamrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05656131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656131.